Management of ischemic heart disease in pregnant women is still difficult, as there is little experience with many of the newer treatments such as clopidogrel. The safety of clopidogrel in pregnancy is unknown, especially in combination with aspirin. Its use during gestation has been described in a few case reports. We describe the case of a 36-year-old woman in her 9th week of pregnancy with a history of chronic hypertension, dyslipidemia and CAD, who required antiplatelet treatment. Clopidogrel and aspirin were administrated until one week before delivery and a healthy child was born at 36 weeks of pregnancy by caesarean section, without any complication.
Introduction
Coronary artery disease (CAD) is rare in women of childbearing age, particularly in pregnancy (1 in 10,000 births) but is a relevant cause of fetal and maternal mortality (1) . The principal risk factors are advanced maternal age, classical cardiovascular risk factors, and severe anaemia. Standard medical treatment for the secondary prevention of CAD includes Clopidogrel and Aspirin. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial demonstrated that the clopidogrel/aspirin combination provides increased efficacy compared with aspirin alone for prevention of cardiovascular events; however, the increased risk of major bleeding offsets a portion of the benefit (2) . The synergy between aspirin and clopidogrel may be secondary to the different platelet activation pathways inhibited by these drugs. The antithrombotic action of aspirin (acetylsalicylic acid) is based on the inhibition of platelet function by acetylation of the platelet cyclooxygenase (COX) at the functionally important amino acid, serine529. Clopidogrel antagonizes platelet aggregation by preventing binding of fibrinogen to the adenosine diphosphate (ADP) receptor. The safety of clopidogrel in pregnancy is unknown, especially in combination with aspirin as routinely administered after coronary stenting. It is classified by Food and Drug Administration (FDA) as category B (3). We describe the case of a pregnant woman with a history of ischemic heart disease who required antiplatelet therapy, treated with aspirin and clopidogrel from 9 to 35 weeks of pregnancy.
Case Report
A 36-year-old Brazilian woman with a history of chronic hypertension, dyslipidemia and CAD had a myocardial infarction (MI) 7 months before she became pregnant. She was treated with percutaneous transluminal coronary angioplasty (PTCA) of the left anterior descending artery, a bare metal stent (BMS) was positioned and she started pharmacological treatment with aspirin 100 mg and clopidogrel 75 mg. Three months later, she had a new episode of angina, caused by in-stent restenosis. A new PTCA was performed, using a drug-eluting stent (DES). She was also receiving treatment with metoprolol, rosuvastatin, telmisartan and pantoprazol. Seven months after MI occurrence, the woman discovered she was pregnant for the first time and stopped all of the medications. Subsequently, she was admitted to the obstetric pathology division of our University Hospital for observation at the 9th week of pregnancy. An episode of chest pain occurred during hospitalization and she was transferred to the Cardiology Unit. Her electrocardiography (ECG) revealed normal sinus rhythm, heart rate 74/ min and no signs of ST deviation were detected. Cardiac markers were negative and cardiac echocardiography only showed a mild left ventricular hypertrophy and a mild left atrium dilatation.
No spontaneous coronary artery dissection, inflammatory disease or autoimmune disorder was diagnosed. No congenital or acquired thrombophilic disease was found.
Cardiologists and hematologists suggested to restart antiplatelet therapy and continue up to 1 year after medicated stent implantation, using aspirin and clopidogrel, because of the high risk of in-stent thrombosis/restenosis. Gynecologists contacted our Teratology Information Service (Telefono Rosso, Rome, Italy) regarding the safety of administering clopidogrel during pregnancy.
Even if few data were available, we suggested to restart antiplatelet therapy using aspirin and clopidogrel because of the importance of maternal treatment. The patient also started methyldopa to consent blood pressure control. Anthypertensive treatment was performed throughout pregnancy.
A new episode of chest pain and tachycardia occurred at 4 months of pregnancy, after a car accident. No ischemic findings were identified.
At 34 weeks of pregnancy, maternal hypertension began to be insensitive to medical treatment and the patient was hospitalized. She continued therapy with clopidogrel and aspirin until the 35th week of pregnancy, replaced by low molecular weight heparin until delivery. A female child was born by caesarean section at 36th week of gestational age. Her weight was 2,410 g, head circumference was 34 cm and length was 48 cm. Apgar score at the first minute was 6, and 9 at 5 minutes. No signs of congenital anomaly were detected at birth. We re-contacted the patient four months after delivery and she confirmed the apparent good health of the baby.
Discussion
The majority of published case reports describe fetal clopidogrel exposure after the first trimester of pregnancy. In this article, we report the case of a patient who resumed clopidogrel from the first trimester and was exposed throughout pregnancy and we also explored previous literature data.
Moreover, this is the first published case in which dual antiplatelet treatment was used to reduce the risk of in-stent restenosis in a high risk pregnant patient, who had a history of CAD and was treated with a DES four months before pregnancy.
Antiplatelet therapy plays an important role to prevent reinfarction. Aspirin (81-325 mg daily) is recommended, and the addition of clopidogrel (75 mg daily) has been shown to provide additional short-term benefit after ST-segment elevation MI and for up to 1 year after non-ST elevation acute coronary syndromes (4) . There are concerns about the appropriate medication regimen post-stenting and/or postinfarct in women of child-bearing age and during pregnancy because of the lack of controlled studies for some medications that have proven benefit in patients post-MI. Clinicians must make a risk-benefit assessment, in order to guarantee maternal safety and to reduce possible fetal risks.
Coronary stenting, with either BMS or DES, has substantially reduced the risk of restenosis after PTCA. DES are metal stents that are coated with a polymer containing an antiproliferative agent, which is gradually released, providing sustained inhibition of the neointimal proliferation that occurs as a result of vascular injury. DES use substantially reduce restenosis but is associated with a low but poorly defined incidence of late stent thrombosis, an event associated with high mortality. However, the safety and effectiveness of DES have not been established in pregnant and lactating woman. Dual antiplatelet therapy after percutaneous coronary intervention was recommended for 1 month after BMS implantation in stable angina; 6-12 months after DES implantation in all patients; 1 year in all patients after ACS, irrespective of revascularization strategy (5) .
Regarding fetal risks, high-dose aspirin exposure in experimental animal studies causes an increase in congenital anomalies (6) (7) (8) (9) . A consistent pattern of congenital anomalies has not been identified in human reports after typical exposures to aspirin (10) . An increase in miscarriage risk after aspirin exposure around the time of conception has been proposed (11) . Aspirin is avoided in late pregnancy due to concerns about premature constriction of the ductus arteriosus and bleeding abnormalities. These concerns do not appear to apply to low-dose (60-100 mg/d) aspirin (12) (13) (14) .
Based on experimental animal studies, Clopidogrel use during pregnancy is not expected to increase the risk of congenital anomalies. Reproduction studies performed in rats and rabbits at doses of up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose), showed no evidence of fetotoxicity due to clopidogrel (3).
The use of clopidogrel during human gestation has been described in a few case reports (15-24) ( Table 1) . Four of these reports (15-18) described a first trimester exposure and in three of these cases treatment was continued throughout pregnancy (15) (16) (17) (18) .
Fetal complications were reported in two cases (18, 19) . Santiago-Diaz et al also presented the case of a 39-year-old first-time mother, in the 6th week of gestation affected by MI, successfully treated with PTCA, clopidogrel and aspirin until delivery. A child was born at term with permeable oval foramen of 0.2 mm, restrictive interventricular muscle communication and moderate mitral insufficiency, which was rated as mild at a 2-month check-up (18). Shah et al described the case of a 33-year-old pregnant woman in the 26th week of pregnancy who presented with a non-ST segment elevation MI secondary to a spontaneous dissection of the left main coronary artery, treated with aspirin, clopidogrel, eptifibatide, atenolol and heparin. She continued to have episodes of angina and she was sent for emergency coronary artery bypass graft surgery (CABG) after the coronary angiogram. The fetus died and was delivered two weeks later (19) .
No data are available regarding increased fetal bleeding risk due to dual antiplatelet therapy. Newborns exposed in utero to low dose aspirin have not been found to have an excessive risk of bleeding abnormalities. However, some proponents of the use of low dose aspirin recommend that treatment be stopped at least five days before the estimated date of delivery to avoid possible hematologic abnormalities in the newborn (25, 26) .
In the present case, in order to ensure safety during the treatment, blood pressure control was maintained during all gestation. Treatment was stopped one week before caesarean section, as recommended by hematologists.
Regarding blood pressure control, methyldopa has been used commonly to treat hypertension during pregnancy. This agent is well suited for long-term use because it does not normally alter maternal cardiac output or blood flow to the kidney or uterus (27, 28) .
Elective cesarean section is often preferred in women with a history of CAD. It avoids a long or stressful labor and allows better control of the time of delivery. It also guarantees the presence of an appropriate medical team including obstetrician, obstetric anesthesiologist, cardiologist, and pediatrician. In the case of a caesarean section, close cardiac monitoring should be undertaken. In the present case, cardiologists recommended caesarean section as the delivery modality, on the basis of the patient's clinical history.
Conclusion
Secondary prevention of coronary events in pregnant patients with a history of CAD remains difficult. Fetal exposure to clopidogrel was described in only a limited number of case reports. First trimester exposure was described in only four of these reports and in three of these cases treatment was continued until delivery.
The safety of this medication during pregnancy cannot be assessed on the basis of few case reports and no controlled studies in pregnant women were performed. Therefore, drug administration can be justified by maternal indication, after risk-benefit assessment. Although the number of published case reports is still limited, these literature data could be helpful in the management of pregnant patients with CAD, requiring a dual antiplatelet therapy.
Pharmacotherapeutical management of these patients is difficult and requires individualized care by a multidisciplinary team. The most appropriate management regimen in these patients is not currently clear and further studies are needed.
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